Bestatin Treatment and the Peripheral Lymphocyte Population in Cancer Patients
Bestatin, a substance produced by Streptomyces olivoreticuli, inhibits certain cell-membrane-associated enzymes and has been shown to augment immune responses in experimental animals. We have determined whether bestatin medication changed the peripheral lymphocyte population in 15 advanced cancer patients. After 2 weeks of daily, 30 mg oral bestatin medication, the lymphocyte counts remained essentially unchanged, but the frequency of E-rosette-forming lymphocytes increased. In vitro stimulation of the lymphocytes with PHA or PPD remained essentially unchanged while the natural-killer activity of the lymphocyte population increased in most patients. Bestatin treatment caused no detectable side effects.
KeywordsPlacebo Toxicity Lymphoma Leukemia Creatinine
Unable to display preview. Download preview PDF.
- 9.Suda H, Takita T, Aoyagi T, Umezawa H (1976) The structure of bestatin. J Antibiot (Tokyo) 29:100–101Google Scholar
- 10.Trinchieri G, Santoli D (1978) Antiviral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 147:1314–1333PubMedCrossRefGoogle Scholar
- 11.Umezawa H (1977) Recent advances in bioactive microbial secondary metabolites. J Antibiot (Tokyo) 30:138–163Google Scholar
- 12.Umezawa H, Aoyagi T, Suda H, Hamada M, Takeuchi T (1976) Bestatin, an inhibitor of aminopeptidase B produced by actinomycetes. J Antibiot (Tokyo) 29:97–99Google Scholar
- 13.Umezawa H, Ishizuka M, Aoyagi T, Takeuchi T (1976) Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase. J Antibiot (Tokyo) 29:857–859Google Scholar